期刊文献+

对秋水仙碱耐受的原发性痛风临床分析

下载PDF
导出
摘要 目的探讨对秋水仙碱耐受的原发性痛风的临床特征及治疗。方法将37例原发性痛风患者根据是否对秋水仙碱治疗耐受分为耐受组和有效组,比较两组的家族史、病程、临床表现、实验室检查及药物不良反应。结果耐受组在家族史、病程、痛风性关节炎发作次数、累及大关节数、并发痛风石、药物不良反应与有效组差异均有统计学意义(均<0.05),在并发肾脏病变、血尿酸水平、白细胞数、血沉等方面差异均无统计学意义(均>0.05)。结论对秋水仙碱耐受的原发性痛风患者,病程更长,并发症更多,治疗需加用非甾体抗炎药或糖皮质激素,但出现药物不良反应更多,预防以降低血尿酸水平为主。
作者 丁佳 吴国富
出处 《现代实用医学》 2013年第8期859-860,共2页 Modern Practical Medicine
  • 相关文献

参考文献9

  • 1Khanna D, Fitz-Gerald JD, Khanna PP, et al. 2012 American College of Rheumat- ology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuicemia [J]. Arthritis Care Res (Ho- boken),2012,64(10): 1431 - 1446.
  • 2Khanna D, Khanna PP, Fitz-Gerald JD, et al. 2012 American College of Rheumat- ology guidelines for management of gout. Part 2:therapy and anti-inflammatory pro phylaxis of acute gouty arthritis [J]. Ar- thritis Care Res(Hoboken),2012,64(10): 1447-1461.
  • 3Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis primary gout [J]. Ar- thritis Rheum[J]. 1977,20(3):895-900.
  • 4Richette P, Bardin T. Gout[3).Lacent,2010, 375(9711):318-328.
  • 5原发性痛风诊断和治疗指南[J].中华风湿病学杂志,2011,15(6):410-413. 被引量:656
  • 6Li R, Sun J, Ren LM, et al. Epidemiology of eight common rheumatic diseases in China:a large-scale cross-sectional survey in Beijing [J]. Rheumatology (Oxford), 2012,51(4):721-729.
  • 7Ng G, Chau EM, Shi Y. Recent develop- ments in immune activation by uric acid crystals [J].Arch Immunol Ther Exp (War- sz),2010,58(4):273-277.
  • 8蒋莉,周京国,青玉凤,谢文光,杨其彬,赵明才,邢艳,魏锦,袁国华,蒋红.Toll样受体2和Toll样受体4及其信号通路在原发性痛风性关节炎发病机制中作用的研究[J].中华风湿病学杂志,2011,15(5):300-304. 被引量:53
  • 9Joosten LA, Netea MG, Mylona E, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-113 production via the ASC/caspase 1 pathway in mono- sodium urate monohydrate crystal-induced gouty arthritis [J].Arthritis Rheum,2010, 62(11 ):3237-3248.

二级参考文献15

  • 1Brikos C, O'Neill LA. Signaling of toll-like receptors. Handb EXD Pharmacol, 2008, 183: 21-50.
  • 2Jayalakshmi K, Kumar S, Masa T, et al. Toll-like receptor signal transduction. Expland Mol Med, 2007, 39: 421-438.
  • 3Sidiropoulos PI, Gouliehnos G, Voloudakis GK, et al. Inflammasomes and rheumatic diseases: evolving concepts. Ann Rheum Dis, 2008, 67: 1382-1389.
  • 4Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 2003, 425: 516-521.
  • 5Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of' the acute arthritis of primary gout. Arthritis Rheum, 1977, 20: 895-900.
  • 6Kenneth J, Thomas D. Analysis of relative gene expression data using real-time quantitative PCR and the 2 [-delta delta C(T)] method. Methods, 2001, 25: 402-408.
  • 7Miao Z, Li C, Chen Y, et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol, 2008, 35: 1859-1864.
  • 8Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000--2005. Ann Rheum Dis, 2008, 67: 960-966.
  • 9Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol, 2010, 11: 373-384.
  • 10Peter S, Ru LB, Anya S, et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystalinduced inflammation. Arthritis Rheum, 2005, 52: 2936- 2946.

共引文献705

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部